An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease
Primary Sponsor
Trans-Tasman Radiation Oncology Group (TROG)
Participating Centres
Current Accrual
Related Post
February 28, 2022
Cancer trial participant hoping to help
The RAVES trial treating prostate cancer Participating in a
June 15, 2021
Individualising radiotherapy for women with DCIS of the breast reduces recurrence after surgery
Ductal carcinoma in situ (DCIS) of the breast is
